These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 32326227)

  • 21. Clinical proteomics in neurodegenerative disorders.
    Zetterberg H; Rüetschi U; Portelius E; Brinkmalm G; Andreasson U; Blennow K; Brinkmalm A
    Acta Neurol Scand; 2008 Jul; 118(1):1-11. PubMed ID: 18279484
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TDP-43 in amyotrophic lateral sclerosis - is it a prion disease?
    Ludolph AC; Brettschneider J
    Eur J Neurol; 2015 May; 22(5):753-61. PubMed ID: 25846565
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metabolic Biomarkers and Neurodegeneration: A Pathway Enrichment Analysis of Alzheimer's Disease, Parkinson's Disease, and Amyotrophic Lateral Sclerosis.
    Kori M; Aydın B; Unal S; Arga KY; Kazan D
    OMICS; 2016 Nov; 20(11):645-661. PubMed ID: 27828769
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biochemical and therapeutic effects of antioxidants in the treatment of Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis.
    Di Matteo V; Esposito E
    Curr Drug Targets CNS Neurol Disord; 2003 Apr; 2(2):95-107. PubMed ID: 12769802
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Extracellular vesicles - propagators of neuropathology and sources of potential biomarkers and therapeutics for neurodegenerative diseases.
    Vassileff N; Cheng L; Hill AF
    J Cell Sci; 2020 Dec; 133(23):. PubMed ID: 33310868
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biomarkers in Neurodegenerative Diseases.
    Jeromin A; Bowser R
    Adv Neurobiol; 2017; 15():491-528. PubMed ID: 28674995
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mass spectrometry based protein biomarkers and drug target discovery and clinical diagnosis in Age-Related progressing neurodegenerative diseases.
    Agrawal I; Tripathi P; Biswas S
    Drug Metab Rev; 2022 Feb; 54(1):22-36. PubMed ID: 35038284
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The deglycase activity of DJ-1 mitigates α-synuclein glycation and aggregation in dopaminergic cells: Role of oxidative stress mediated downregulation of DJ-1 in Parkinson's disease.
    Sharma N; Rao SP; Kalivendi SV
    Free Radic Biol Med; 2019 May; 135():28-37. PubMed ID: 30796974
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dysregulated miRNAs as Biomarkers and Therapeutical Targets in Neurodegenerative Diseases.
    Gentile G; Morello G; La Cognata V; Guarnaccia M; Conforti FL; Cavallaro S
    J Pers Med; 2022 May; 12(5):. PubMed ID: 35629192
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modulation of Parkinson's Disease Associated Protein Rescues Alzheimer's Disease Degeneration.
    Nunomura A; Zhu X; Perry G
    J Alzheimers Dis; 2017; 55(1):73-75. PubMed ID: 27802241
    [TBL] [Abstract][Full Text] [Related]  

  • 31. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
    Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
    Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aβ, Tau, and α-Synuclein aggregation and integrated role of PARK2 in the regulation and clearance of toxic peptides.
    Kumar D; Kumar P
    Neuropeptides; 2019 Dec; 78():101971. PubMed ID: 31540705
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnostic and Therapeutic Potential of Exosomal MicroRNAs for Neurodegenerative Diseases.
    He M; Zhang HN; Tang ZC; Gao SG
    Neural Plast; 2021; 2021():8884642. PubMed ID: 34054944
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pathological properties of the Parkinson's disease-associated protein DJ-1 in alpha-synucleinopathies and tauopathies: relevance for multiple system atrophy and Pick's disease.
    Neumann M; Müller V; Görner K; Kretzschmar HA; Haass C; Kahle PJ
    Acta Neuropathol; 2004 Jun; 107(6):489-96. PubMed ID: 14991385
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Clinical Significance of Cerebrospinal Fluid Reticulon 4 (RTN4) Levels in the Differential Diagnosis of Neurodegenerative Diseases.
    Kulczyńska-Przybik A; Dulewicz M; Słowik A; Borawska R; Kułakowska A; Kochanowicz J; Mroczko B
    J Clin Med; 2021 Nov; 10(22):. PubMed ID: 34830564
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Friends or Foes: Matrix Metalloproteinases and Their Multifaceted Roles in Neurodegenerative Diseases.
    Brkic M; Balusu S; Libert C; Vandenbroucke RE
    Mediators Inflamm; 2015; 2015():620581. PubMed ID: 26538832
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oxidative stress and mitochondrial dysfunction-linked neurodegenerative disorders.
    Islam MT
    Neurol Res; 2017 Jan; 39(1):73-82. PubMed ID: 27809706
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of extracellular vesicles in neurodegenerative diseases.
    Quek C; Hill AF
    Biochem Biophys Res Commun; 2017 Feb; 483(4):1178-1186. PubMed ID: 27659705
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The relationship between four GWAS-identified loci in Alzheimer's disease and the risk of Parkinson's disease, amyotrophic lateral sclerosis, and multiple system atrophy.
    Chen Y; Cao B; Chen X; Ou R; Wei Q; Zhao B; Wu Y; Yuan L; Shang HF
    Neurosci Lett; 2018 Nov; 686():205-210. PubMed ID: 30144538
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Involvement of alpha-synuclein in Parkinson's disease and other neurodegenerative disorders.
    Krüger R; Müller T; Riess O
    J Neural Transm (Vienna); 2000; 107(1):31-40. PubMed ID: 10809401
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.